Neutropenia and Neutropenic Complications in ABVD Chemotherapy for Hodgkin Lymphoma
A combination of Adriamycin (a.k.a. Doxorubicin), Bleomycin, Vinblastine, and Dacarbazine (ABVD) is the most commonly used chemotherapy regime for Hodgkin lymphoma. This highly effective treatment is associated with a significant risk of neutropenia. Various strategies are adopted to counter this co...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2011-01-01
|
| Series: | Advances in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2011/656013 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832554023933181952 |
|---|---|
| author | Bhanu Vakkalanka Brian K. Link |
| author_facet | Bhanu Vakkalanka Brian K. Link |
| author_sort | Bhanu Vakkalanka |
| collection | DOAJ |
| description | A combination of Adriamycin (a.k.a. Doxorubicin), Bleomycin, Vinblastine, and Dacarbazine (ABVD) is the most commonly used chemotherapy regime for Hodgkin lymphoma. This highly effective treatment is associated with a significant risk of neutropenia. Various strategies are adopted to counter this commonly encountered problem, including dose modification, use of colony stimulating factors, and prophylactic or therapeutic use of antibiotics. Data to support these approaches is somewhat controversial, and in keeping with the paucity of definitive evidence, there is a wide disparity in the management of neutropenia in patients receiving ABVD chemotherapy. This paper summarizes the evidence for managing ABVD-related neutropenia during the treatment of Hodgkin lymphoma. |
| format | Article |
| id | doaj-art-87522fae11134de596f17e18f7ce7831 |
| institution | Kabale University |
| issn | 1687-9104 1687-9112 |
| language | English |
| publishDate | 2011-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Advances in Hematology |
| spelling | doaj-art-87522fae11134de596f17e18f7ce78312025-02-03T05:52:36ZengWileyAdvances in Hematology1687-91041687-91122011-01-01201110.1155/2011/656013656013Neutropenia and Neutropenic Complications in ABVD Chemotherapy for Hodgkin LymphomaBhanu Vakkalanka0Brian K. Link1Department of Internal Medicine, Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA 52242, USADepartment of Internal Medicine, Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA 52242, USAA combination of Adriamycin (a.k.a. Doxorubicin), Bleomycin, Vinblastine, and Dacarbazine (ABVD) is the most commonly used chemotherapy regime for Hodgkin lymphoma. This highly effective treatment is associated with a significant risk of neutropenia. Various strategies are adopted to counter this commonly encountered problem, including dose modification, use of colony stimulating factors, and prophylactic or therapeutic use of antibiotics. Data to support these approaches is somewhat controversial, and in keeping with the paucity of definitive evidence, there is a wide disparity in the management of neutropenia in patients receiving ABVD chemotherapy. This paper summarizes the evidence for managing ABVD-related neutropenia during the treatment of Hodgkin lymphoma.http://dx.doi.org/10.1155/2011/656013 |
| spellingShingle | Bhanu Vakkalanka Brian K. Link Neutropenia and Neutropenic Complications in ABVD Chemotherapy for Hodgkin Lymphoma Advances in Hematology |
| title | Neutropenia and Neutropenic Complications in ABVD Chemotherapy for Hodgkin Lymphoma |
| title_full | Neutropenia and Neutropenic Complications in ABVD Chemotherapy for Hodgkin Lymphoma |
| title_fullStr | Neutropenia and Neutropenic Complications in ABVD Chemotherapy for Hodgkin Lymphoma |
| title_full_unstemmed | Neutropenia and Neutropenic Complications in ABVD Chemotherapy for Hodgkin Lymphoma |
| title_short | Neutropenia and Neutropenic Complications in ABVD Chemotherapy for Hodgkin Lymphoma |
| title_sort | neutropenia and neutropenic complications in abvd chemotherapy for hodgkin lymphoma |
| url | http://dx.doi.org/10.1155/2011/656013 |
| work_keys_str_mv | AT bhanuvakkalanka neutropeniaandneutropeniccomplicationsinabvdchemotherapyforhodgkinlymphoma AT brianklink neutropeniaandneutropeniccomplicationsinabvdchemotherapyforhodgkinlymphoma |